Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth

References

• Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779-90; PMID:12121660; http://dx.doi.org/10.1016/S1074-7613(02)00324-2
   PubMed Web of Science ®Google Scholar
• Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997; 94:12041-6; PMID:9342359; http://dx.doi.org/10.1073/pnas.94.22.12041
   PubMed Web of Science ®Google Scholar
• Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37:3021-9; PMID:17874423; http://dx.doi.org/10.1002/eji.200737810
   PubMed Web of Science ®Google Scholar
• Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450:566-9; PMID:18033300; http://dx.doi.org/10.1038/nature06306
   PubMed Web of Science ®Google Scholar
• Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172:2225-31; PMID:14764690; http://dx.doi.org/10.4049/jimmunol.172.4.2225
   PubMed Web of Science ®Google Scholar
• Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11:1093-101; PMID:20953201; http://dx.doi.org/10.1038/ni.1952
   PubMed Web of Science ®Google Scholar
• Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13:290-9; PMID:22306691; http://dx.doi.org/10.1038/ni.2227
   PubMed Web of Science ®Google Scholar
• Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, Flies D, Boone T, Hsu H, Fu YX, Nagata S, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000; 6:283-9; PMID:10700230; http://dx.doi.org/10.1038/73136
   PubMedGoogle Scholar
• Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7:929-36; PMID:16906167; http://dx.doi.org/10.1038/ni1375
   PubMed Web of Science ®Google Scholar
• Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-8; PMID:17496900; http://dx.doi.org/10.1038/nm1585
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25:221-42; PMID:17291186; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104758
   PubMed Web of Science ®Google Scholar
• Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O'Shea JJ, Hunter CA. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007; 8:1363-71; PMID:17994025; http://dx.doi.org/10.1038/ni1537
   PubMed Web of Science ®Google Scholar
• Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007; 8:1380-9; PMID:17994022; http://dx.doi.org/10.1038/ni1541
   PubMed Web of Science ®Google Scholar
• Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, Das Sarma J, Gran B, Zhang GX, Rostami A. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007; 179:3268-75; PMID:17709543; http://dx.doi.org/10.4049/jimmunol.179.5.3268
   PubMed Web of Science ®Google Scholar
• Hunter CA, Kastelein R. Interleukin-27: balancing protective and pathological immunity. Immunity 2012; 37:960-9; PMID:23244718; http://dx.doi.org/10.1016/j.immuni.2012.11.003
   PubMed Web of Science ®Google Scholar
• Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, Lee BW, Chua KY. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011; 187:462-71; PMID:21613618; http://dx.doi.org/10.4049/jimmunol.1100259
   PubMed Web of Science ®Google Scholar
• Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 2012; 61:1519-26; PMID:22427377; http://dx.doi.org/10.2337/db11-0784
   PubMed Web of Science ®Google Scholar
• Neufert C, Becker C, Wirtz S, Fantini MC, Weigmann B, Galle PR, Neurath MF. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 2007; 37:1809-16; PMID:17549733; http://dx.doi.org/10.1002/eji.200636896
   PubMed Web of Science ®Google Scholar
• Huber M, Steinwald V, Guralnik A, Brustle A, Kleemann P, Rosenplanter C, Decker T, Lohoff M. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 2008; 20:223-34; PMID:18156621; http://dx.doi.org/10.1093/intimm/dxm139
   PubMed Web of Science ®Google Scholar
• Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med 2011; 208:115-23; PMID:21173106; http://dx.doi.org/10.1084/jem.20100410
   PubMed Web of Science ®Google Scholar
• Wojno ED, Hosken N, Stumhofer JS, O'Hara AC, Mauldin E, Fang Q, Turka LA, Levin SD, Hunter CA. A role for IL-27 in limiting T regulatory cell populations. J Immunol 2011; 187:266-73; PMID:21622862; http://dx.doi.org/10.4049/jimmunol.1004182
   PubMedGoogle Scholar
• Murugaiyan G, Saha B. IL-27 in tumor immunity and immunotherapy. Trends Mol Med 2013; 19:108-16; PMID:23306374; http://dx.doi.org/10.1016/j.molmed.2012.12.002
   PubMedGoogle Scholar
• Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. IL-27 enhances the survival of tumor antigen-specific CD8(+) T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol 2013; 43:468-79; PMID:23225163; http://dx.doi.org/10.1002/eji.201242930
   PubMed Web of Science ®Google Scholar
• Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol 2005; 175:1686-93; PMID:16034109; http://dx.doi.org/10.4049/jimmunol.175.3.1686
   PubMedGoogle Scholar
• Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol 2011; 41:47-59; PMID:21182076; http://dx.doi.org/10.1002/eji.201040804
   PubMedGoogle Scholar
• Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y, Bai XF. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013; 190:2415-23; PMID:23345334; http://dx.doi.org/10.4049/jimmunol.1202535
   PubMed Web of Science ®Google Scholar
• Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR, Jr., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008; 28:546-58; PMID:18387831; http://dx.doi.org/10.1016/j.immuni.2008.02.017
   PubMed Web of Science ®Google Scholar
• Wang LX, Talebian F, Liu JQ, Khattabi M, Yu L, Bai XF. IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours. Scand J Immunol 2012; 75:273-81; PMID:22050574; http://dx.doi.org/10.1111/j.1365-3083.2011.02662.x
   PubMedGoogle Scholar
• Liu Y, Peng Y, Mi M, Guevara-Patino J, Munn DH, Fu N, He Y. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol 2009; 182:5960-9; PMID:19414747; http://dx.doi.org/10.4049/jimmunol.0900008
   PubMed Web of Science ®Google Scholar
• Sauer KA, Maxeiner JH, Karwot R, Scholtes P, Lehr HA, Birkenbach M, Blumberg RS, Finotto S. Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. J Immunol 2008; 181:6148-57; PMID:18941205; http://dx.doi.org/10.4049/jimmunol.181.9.6148
   PubMedGoogle Scholar
• Shinozaki Y, Wang S, Miyazaki Y, Miyazaki K, Yamada H, Yoshikai Y, Hara H, Yoshida H. Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int J Cancer 2009; 124:1372-8; PMID:19089917; http://dx.doi.org/10.1002/ijc.24107
   PubMedGoogle Scholar
• Natividad KD, Junankar SR, Mohd Redzwan N, Nair R, Wirasinha RC, King C, Brink R, Swarbrick A, Batten M. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLOS ONE 2013; 8:e57469; PMID:23554861; http://dx.doi.org/10.1371/journal.pone.0057469
   PubMed Web of Science ®Google Scholar
• Wei J, Xia S, Sun H, Zhang S, Wang J, Zhao H, Wu X, Chen X, Hao J, Zhou X, et al. Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells. J Immunol 2013; 191:500-8; PMID:23733881; http://dx.doi.org/10.4049/jimmunol.1300328
   PubMedGoogle Scholar
• Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW, Jr., Yu C, Shi FD, Whitacre CC, Trgovcich J, et al. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 2012; 188:3099-106; PMID:22387555; http://dx.doi.org/10.4049/jimmunol.1100106
   PubMed Web of Science ®Google Scholar
• Morishima N, Mizoguchi I, Okumura M, Chiba Y, Xu M, Shimizu M, Matsui M, Mizuguchi J, Yoshimoto T. A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol 2010; 2010:605483; PMID:20454646; http://dx.doi.org/10.1155/2010/605483
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176:7317-24; PMID:16751375; http://dx.doi.org/10.4049/jimmunol.176.12.7317
   PubMed Web of Science ®Google Scholar
• Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006; 66:6395-404; PMID:16778218; http://dx.doi.org/10.1158/0008-5472.CAN-05-4087
   PubMed Web of Science ®Google Scholar
• Kim G, Shinnakasu R, Saris CJ, Cheroutre H, Kronenberg M. A novel role for IL-27 in mediating the survival of activated mouse CD4 T lymphocytes. J Immunol 2013; 190:1510-8; PMID:23335749; http://dx.doi.org/10.4049/jimmunol.1201017
   PubMedGoogle Scholar
• Hall AO, Beiting DP, Tato C, John B, Oldenhove G, Lombana CG, Pritchard GH, Silver JS, Bouladoux N, Stumhofer JS, et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 2012; 37:511-23; PMID:22981537; http://dx.doi.org/10.1016/j.immuni.2012.06.014
   PubMed Web of Science ®Google Scholar
• Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190:995-1004; PMID:10510089; http://dx.doi.org/10.1084/jem.190.7.995
   PubMed Web of Science ®Google Scholar
• Asseman C, Read S, Powrie F. Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. J Immunol 2003; 171:971-8; PMID:12847269; http://dx.doi.org/10.4049/jimmunol.171.2.971
   PubMed Web of Science ®Google Scholar
• Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006; 177:5852-60; PMID:17056509; http://dx.doi.org/10.4049/jimmunol.177.9.5852
   PubMedGoogle Scholar
• Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, Tomczak M, Rogers AB, Horwitz BH, Fox JG. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 2003; 63:6042-50; PMID:14522933
   PubMed Web of Science ®Google Scholar
• Liu Z, Yu J, Carson WE, 3rd, Bai XF. The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res 2013; 5:470-80; PMID:23977407
   PubMedGoogle Scholar
• Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004; 173:7170-82; PMID:15585838; http://dx.doi.org/10.4049/jimmunol.173.12.7170
   PubMed Web of Science ®Google Scholar
• Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64:1152-6; PMID:14871851; http://dx.doi.org/10.1158/0008-5472.CAN-03-2084
   PubMed Web of Science ®Google Scholar
• Chiyo M, Shimozato O, Iizasa T, Fujisawa T, Tagawa M. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res 2004; 24:3763-7; PMID:15736409
   PubMed Web of Science ®Google Scholar
• Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009; 182:4328-38; PMID:19299733; http://dx.doi.org/10.4049/jimmunol.0800471
   PubMed Web of Science ®Google Scholar
• Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 2010; 184:2348-54; PMID:20139275; http://dx.doi.org/10.4049/jimmunol.0902371
   PubMed Web of Science ®Google Scholar
• Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R, Bai XF. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One 2012; 7:e31442; PMID:22319630; http://dx.doi.org/10.1371/journal.pone.0031442
   PubMedGoogle Scholar
• Liu JQ, Joshi PS, Wang C, El-Omrani HY, Xiao Y, Liu X, Hagan JP, Liu CG, Wu LC, Bai XF. Targeting activation-induced cytidine deaminase overcome tumor evasion of immunotherapy by CTLs. J Immunol 2010; 184:5435-43; PMID:20404277; http://dx.doi.org/10.4049/jimmunol.0903322
   PubMedGoogle Scholar
• Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001; 61:1107-12; PMID:11221840
   PubMedGoogle Scholar